Glofitamab Cost-Effectiveness: Conditional Reim...

By HEOR Staff Writer

February 17, 2026

Glofitamab Cost-Effectiveness in R/R DLBCL Reimbursement Glofitamab cost-effectiveness analysis by Zorginstituut Nederland supports conditional inclusion of glofitamab (Columvi...
NICE Endorses Pegzilarginase for Treating Arginase Deficiency
Transformative PBM Reform Legislation Signed into Law
Disrupting Prescription Drug Pricing: Mark Cuban’s Cost-Plus Vision
Pharmaceutical Tender Investigation Sparks Regulatory Scrutiny in South Africa
South Africa Health Reform: Navigating Innovations and Challenges for 2026
Enhancing Early-Stage Cancer Treatment: Overcoming Barriers for Better Outcomes
European Pharma Competitiveness: A Cornerstone for EU Economic Resilience
Tislelizumab NSCLC Inclusion Recommended for Dutch Health Package
Launch of TrumpRx Drug Pricing: Savings on Essential Medications
Ozempic Public Funding Approval in Portugal: Key Insights and Implications
NICE Endorses Dupilumab for Eosinophilic COPD Treatment
NICE Endorses Talazoparib Enzalutamide for Prostate Cancer Treatment